Here are 10 small‑cap biotech stocks with notable
upcoming catalysts in 2025—ranging from trial readouts and FDA decisions to
pivotal data and corporate milestones:
🔬 Top 10 Small-Cap
Biotechs with Upcoming Catalysts for 2025
1. Crinetics Pharmaceuticals (NASDAQ: CRNX)
- Catalyst:
FDA PDUFA deadline for paltusotine (oral acromegaly treatment) expected by
September 25, 2025 (reddit.com,
en.wikipedia.org).
- Focused
on endocrine diseases and advancing pipeline beyond acromegaly (en.wikipedia.org).
Stock market information for Crinetics Pharmaceuticals
Inc (CRNX)
- Crinetics
Pharmaceuticals Inc is a equity in the USA market.
- The
price is 32.33 USD currently with a change of -0.73 USD (-0.02%) from the
previous close.
- The
latest open price was 33.1 USD and the intraday volume is 420639.
- The
intraday high is 33.34 USD and the intraday low is 32.32 USD.
- The
latest trade time is Wednesday, June 11, 23:45:00 +0300.
2. Viking Therapeutics
- Catalyst:
Late-stage trial start for injectable weight-loss drug (GLP‑1/GIP);
mid-stage data readout for oral candidate due in 2025 (barrons.com).
- Strong
analyst sentiment: Jefferies forecasts ~223% upside (barrons.com).
3. Insmed (NASDAQ: INSM)
- Catalyst:
Phase III/inhalable powder treprostinil palmitil for pulmonary arterial
hypertension; recent results exceeded expectations; full Phase III data
due in 2025 (investors.com).
4. Kymera Therapeutics
- Catalyst:
Phase I for KT‑621 (oral STAT6 degrader for dermatitis/asthma); next-stage
readouts expected late 2025–early 2026 (barrons.com).
- Shares
rose ~50% on initial results; further trials underway (barrons.com).
5. Arcutis Biotherapeutics (NASDAQ: ARQT)
- Catalyst:
Technical breakout potential near $17.75; continued quarterly readouts
with rising sales (33% last quarter) (investors.com).
- Upcoming
investor calls/publication strategies may accelerate momentum.
6. Rhythm Pharmaceuticals (NASDAQ: RYTM)
- Catalyst:
With FDA-approved Imcivree for genetic obesity, further label expansion or
mid-to-late-stage trial results anticipated in 2025 (investors.com).
- Institutional
buying trends and revenue growth support upcoming readouts .
7. BeOne Medicines (Ticker: ONC)
- Catalyst:
Early human data in solid tumor oncology; multiple upcoming trials in 2025
.
- Q1
2025 marked first profit; strong institutional support (investors.com).
8. Mesoblast Ltd & Capricor Therapeutics
- Catalyst:
Stem-cell therapies targeting GvHD, heart failure, Duchenne muscular
dystrophy—key FDA decisions expected in H2 2025 (marketwatch.com).
- Maxim
Group flags pivotal year for approvals and stock catalysts (marketwatch.com).
9. Acelyrin (NASDAQ: SLRN)
- Catalyst:
Phase III results for lonigutamab in thyroid eye disease; shareholder vote
on Alumis merger around May 2025 (en.wikipedia.org).
- Merger
closing and clinical readouts may drive volatility .
10. ADC Therapeutics & Foghorn Therapeutics &
Pyxis Oncology
- Catalysts:
Multiple preclinical/early clinical updates presented at AACR (April
2025) (ozmosi.com).
- ADC
Therapeutics (ADCT): Readouts on 6 ADC programs (Claudin‑6, NaPi2b,
etc.).
- Foghorn
(FHTX): Preclinical updates on EP300, FHD609, FHD909.
- Pyxis
Oncology (PYXS): Phase I ADC and Siglec‑15 antibody data.
🔎 How to Monitor These
Catalysts
- FDA
PDUFA dates (Crinetics, Mesoblast/Capricor, Viking)
- Trial
readouts/ASC presentations (Kymera, Insmed, ADC Therapeutics, Foghorn,
Pyxis)
- M&A/news
events (BeOne, Acelyrin merger)
📊 Summary Table
|
Ticker |
Company |
Upcoming Catalyst |
Timeframe |
|
CRNX |
Crinetics |
PDUFA paltusotine NDA |
Sep 25, 2025 |
|
Viking |
Viking Therapeutics |
Injectable Phase III, oral Phase II data |
From mid-2025 |
|
INSM |
Insmed |
PAH inhalable Phase III readout |
Mid-to-late 2025 |
|
Kymera |
Kymera Therapeutics |
Dermatitis/asthma Phase I → Phase II |
Late 2025 – 2026 |
|
ARQT |
Arcutis Biotherapeutics |
Continued quarterly updates |
Throughout 2025 |
|
RYTM |
Rhythm Pharmaceuticals |
Label expansion/trial updates |
2025 |
|
ONC |
BeOne Medicines |
Solid tumor trial data |
2025 |
|
Mesoblast/Capricor |
Stem-cell stocks |
FDA decisions |
H2 2025 |
|
SLRN |
Acelyrin |
EMA/merger vote + Phase III readout |
May–Q3 2025 |
|
ADCT/FHTX/PYXS |
AACR presenters |
Academic readouts on multiple programs |
April 2025 |
⚠️ A Word of Caution
Small-cap biotech involves high volatility—catalyst events
often drive sharp price swings, both up and down. Thorough due diligence is
essential.
Let me know if you'd like a deeper dive into any of these
companies!
